Reseña del libro "Protein Serine/Threonine Kinases in Neurodegenerative Disorders (en Inglés)"
Protein Serine/Threonine Kinases in Neurodegenerative Disorders provides a comprehensive overview of protein serine/threonine kinases (STKs) in health and disease. It also discusses protein kinase inhibitors and their potential role in modulating and treating neurodegenerative diseases. The book begins with an introduction to protein kinases and inhibitors, followed by detailed discussions on different types of kinases, including protein kinase C (PKC), AMP-activated protein kinase (AMPK), Death-associated protein kinase 1 (DAPK1), cyclin-dependent kinases (CDKs), glycogen synthase kinases (GSKs), Rho-associated protein kinase (ROCK), microtubule affinity regulating kinases (MARK), mammalian target of Rapamycin (mTOR), Leucine-rich repeat kinase 2 (LRRK2), PTEN-induced kinase 1 (PINK1), dual-specificity tyrosine phosphorylation-regulated kinase (DYRKs), and their roles in neurodegenerative disease, potential inhibitors, and therapeutic mechanisms. Protein Serine/Threonine Kinases in Neurodegenerative Disorders features 23 chapters written by renowned experts in kinases field. It explores novel targets modulated by protein kinases, including non-coding RNAs (ncRNAs), mitogen-activated protein kinases (MAPKs) activated by tyrosine receptor kinases, and their roles in neurodegeneration. It also discusses the nexus between glycogen synthase kinases (GSKs) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their metabolic regulation role in neurodegeneration. The modulatory effects of protein kinase B (PKB/AKT) pathways in various neurodegenerative disorders, particularly Parkinson's disease, are also examined. The book sheds light on bioactive compounds from natural products that target kinases. The book explains the role of different kinases in various pathogenic pathways and mechanisms involved in neurodegeneration, including regulated cell death, autophagy, synaptic dysfunction, and neuroinflammation. It also discusses splicing kinases in regulating splicing factor phosphorylation and details how aberrant kinase activity leads to splicing defects that contribute to neurodegenerative pathologies. This book emphasizes bridging laboratory research with clinical applications, focusing on translational opportunities. It includes insights from FDA regulatory experts on therapeutic applications and safety considerations of targeting kinases, highlighting the importance of balancing efficacy and safety, particularly in relation to drug-induced liver injury associated with kinase inhibitors. Finally, the book discusses the obstacles and opportunities for the potential repositioning of protein kinase inhibitors in neurodegenerative disorders.
